Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 15 November 2011. Read More
— Research and development agreement signed with Mayo Clinic — Oxford, UK – 31 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
— Third ocular product partnered with Sanofi approved to enter clinical development — Oxford, UK – 18 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Click here to download the full 2011 interim results statement.Click here to download the 2011 interim results slide deck. Read More
— Positive interim review of fourth patient cohort by Data Monitoring Committee — Oxford, UK – 4 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
— RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford, UK – 22 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy… Read More
— ‘In vivo’ diagnostic rights granted for cancer imaging — Oxford, UK – 7 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
–Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy– Oxford, UK – 24 May 2011: Oxford BioMedica (LSE:OXB), a leading… Read More
— Six-month data from third cohort presented at ASGCT 14th Annual Meeting —— Highest efficacy results to date with 43% average motor function improvement —… Read More
Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today publishes its interim management statement for the period from 1 January to 17 May 2011. Read More
— Diagnostic rights secured for Investigational New Drug application — Oxford, UK – 4 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD) will be… Read More